# A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

> **NCT06348199** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 555 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** SB27
- **DRUG:** Keytruda

## Key facts

- **NCT ID:** NCT06348199
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-12
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 555 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348199, "A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06348199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*